Rege Nephro

Executive Summary

Rege Nephro is a Japanese biotechnology company pioneering regenerative medicine for kidney diseases using induced pluripotent stem cell (iPSC) technology. Founded in 2019 and based in Kyoto, the company develops nephron progenitor cells (NPCs), erythropoietin-producing cells, and ureteral blast cells from pluripotent stem cells. Its lead therapeutic programs target autosomal dominant polycystic kidney disease (ADPKD) and renal anemia, two large unmet medical needs. The company operates at the preclinical stage and has raised approximately ¥3.3 billion (~$21 million) to date. Rege Nephro's platform holds significant potential to address the shortage of donor kidneys and the limitations of current dialysis or erythropoietin-stimulating agent therapies. By generating functional kidney cell types, the company aims to restore kidney function or treat complications like anemia. The approach aligns with Japan's strategic focus on regenerative medicine and could open new treatment paradigms for chronic kidney disease. However, as a preclinical entity, Rege Nephro faces substantial technical and regulatory hurdles, including scalability, safety, and efficacy in humans. Its progress will depend on successful validation in animal models, process development, and eventual clinical translation. Given the early stage, a conviction score of 68 reflects cautious optimism based on the technology's promise and funding, balanced against the high risks inherent in cell therapy development.

Upcoming Catalysts (preview)

• H2 2026Initiation of IND-enabling studies for ADPKD NPC therapy40% success
• Q2 2026Publication of preclinical proof-of-concept data in renal anemia model70% success
• 2026Strategic partnership or licensing deal for iPSC manufacturing or Japan rights30% success